Ping Luo
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (39)
Year:
2026
Year:
2026
Year:
2026
Year:
2024
Background Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. HCC diagnosis, monitoring, and treatment decisions rely predominantly on imaging. Curative surgery is limited to those with disease confined to the liver, but recurrence is common. Detection of HCC by mutational profiling of blood plasma cell-free DNA (cfDNA) is limited by mutational heterogeneity and difficulty obtaining tumor tissue to guide targeted gene panels. In contrast, DNA methylation patterns reveal biological processes without need for prior mutational knowledge. We evaluated cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-Seq) for HCC detection and monitoring of recurrence after curative-intent surgery. Methods We identified patients undergoing liver transplantation or resection and collected blood at surgery (baseline) and every 3 months for two years (follow-up). We performed cfMeDIP-Seq followed by machine learning to i) develop an HCC classifier based on 300 differentially methylated regions in a Discovery cohort of 35 living liver donors (healthy controls) and 52 baseline samples from HCC patients; ii) test the classifier in a separate Validation cohort of 37 baseline and 112 follow-up samples from 37 patients; and iii) assign an HCC methylation score (HMS) to samples based on their probability (0.0-1.0) of containing HCC-derived cfDNA. We assessed the relationships between HMS and clinical variables. Results cfMeDIP-Seq to a depth of 101-129 (median 113) million reads per sample succeeded in 201 plasma samples from 89 HCC patients (57 transplant and 32 resection) and 35 healthy controls. In the Discovery cohort, the HCC classifier identified HCC with 97% sensitivity and 99% specificity (mean AUROC = 0.999). In the Validation cohort, the classifier identified HCC with 97% accuracy and HMS distinguished baseline HCC samples, follow-ups with recurrence, follow-ups without recurrence, and controls. Baseline HMS>0.9 was associated with higher recurrence risk in Cox regression (HR 3.43 (95% CI 1.30-9.06), p=0.013). In all patients with follow-up samples, HMS decreased by 3-44% (median 17%) within the first 13 weeks after surgery. Subsequently, HMS trajectory of recurrent and non-recurrent patients diverged, with HMS rise relative to the first post-surgery timepoint associated with clinical recurrence. HMS functioned independently of other clinicopathologic variables. Conclusion Tumor-agnostic cfDNA methylomes accurately detect HCC and predict recurrence after liver resection or transplantation. This approach may have important implications for HCC diagnosis, treatment, and monitoring.
Year:
2024
Multivariable analysis of survival using cancer-specific methylation (CSM) scores at baseline and cycle 3 of pembrolizumab. We computed CSM scores across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown in a multivariable analysis including cohort, PD-L1 expression, and tumor mutation burden (TMB).
Year:
2024
Validation of the 200 CpG signature using publicly available WGBS data. A 200 CpG signature was generated using 450K array data from TCGA PanCanAtlas. We validated this signature in publicly available data from WGBS of esophageal squamous cell carcinoma and adjacent normal tissue (GSE149608), as well as breast cancers (GSE186747). (A) A heatmap of methylation beta values of our signature sites demonstrates that the methylation signature demonstrated hypermethylation in both esophageal and breast cancers relative to adjacent normal esophageal tissue. (B) A scatter plot of mean beta values, with one point for each signature window is shown. This confirms that any differentially methylated windows were generally hypermethylated in tumor relative to normal. (C) Methylation signature scores were computed by summing the beta values across all sites for each sample. This verified that tumors demonstrated higher scores than adjacent normal tissue.
Year:
2024
Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene panels. We analyzed genome-wide methylation and fragment-length profiles using cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq) in 204 plasma samples from 87 patients before and during treatment with pembrolizumab from a pan-cancer phase II investigator-initiated trial (INSPIRE). We trained a pan-cancer methylation signature using independent methylation array data from The Cancer Genome Atlas to quantify cancer-specific methylation (CSM) and fragment-length score (FLS) for each sample. CSM and FLS are strongly correlated with tumor-informed ctDNA levels. Early kinetics of CSM predict overall survival and progression-free survival, independently of tumor type, PD-L1, and tumor mutation burden. Early kinetics of FLS are associated with overall survival independently of CSM. Our tumor-naïve mutation-agnostic ctDNA approach integrating methylomics and fragmentomics could predict outcomes in patients treated with pembrolizumab. Significance: Analysis of methylation and fragment length in plasma using cfMeDIP-seq provides a tumor-naive approach to measure ctDNA with results comparable with a tumor-informed bespoke ctDNA. Early kinetics within the first weeks of treatment in methylation and fragment quantity can predict outcomes with pembrolizumab in patients with various advanced solid tumors. This article is featured in Selected Articles from This Issue, p. 897
Year:
2024
Multivariable analysis of OS and PFS using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a bespoke targeted approach across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown in a multivariable analysis including cohort, PD-L1 expression, and tumor mutation burden (TMB).
Year:
2024
Predicting survival outcomes using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a tumor-informed bespoke approach across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown, with hazard ratios and p-values adjusted for cohort using a Cox model. PFS analysis at cycle 3 excludes one patient who progressed before the collection of cycle 3 sample.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (23)
Raymond H. Kim
Associate Professor
University Health Network
Aaron R. Hansen
Medical Oncologist
University Health Network
David Malkin
University of Toronto
Albiruni R. Abdul Razak
University Health Network
Dionysios Watson
University of Miami School of Medicine
David G. Coffey
Assistant Professor
University of Miami School of Medicine
Anna Spreafico
University Health Network
Wei Xu
University of Toronto
Jonathan Schatz
Associate Professor
University of Miami School of Medicine
Pamela S. Ohashi
University of Toronto
Philip Awadalla
Professor of Molecular Genetics and Director
University of Oxford
Lillian L. Siu
University Health Network
Gonzalo Sapisochin
University of Toronto
Andrea S. Doria
Hospital for Sick Children
Philippe L. Bedard
University Health Network
J. Javier Diaz-Mejia
Head of Data Science
-
Michele Ceccarelli
Research Professor at University of Miami
University of Miami
Jack Brzezinski
Associate Professor
University of Washington
Edus Warren
Fred Hutchinson Cancer Research Center
Trevor J. Pugh
Professor
University Health Network
Francesco Maura
Assistant Professor
Sylvester Comprehensive Cancer Center
Jonathan Finlay
Emeritus Professor
The Ohio State University College of Medicine
Edgar Ernesto Gonzalez Kozlova
Assistant Professor
-
Make your next move.
Prepare your application
Review drafts before you send them.